PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TARPERPRUMIG IN ADULT PARTICIPANTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS

Registry ID

ALXN1820-ANCA-201

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ALEXION PHARMACEUTICALS INC

Start date

2026-01-15

Last update

2025-08-28

Conditions

• ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS

Related clinical trials

• A PHASE 3, OPEN-LABEL, UNCONTROLLED SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, AND SAFETY OF AVACOPAN IN COMBINATION WITH A RITUXIMAB OR A CYCLOPHOSPHAMIDE-CONTAINING REGIMEN IN CHILDREN FROM 6 YEARS TO < 18 YEARS OF AGE WITH ACTIVE ANCA-ASSOCIATED VASCULITIS (AAV)

View on source registry